natgillin/translations-raw huggingface dataset:
Careful consideration should be given to the patient’s clinical status prior to administration of Myozyme.
Pred uporabo zdravila Myozyme je treba temeljito preučiti bolnikovo klinično stanje.
Careful follow-up for weight suggests that children and adolescents who took Intuniv in the study (i.e., treatment for 7 days per week throughout the year) have demonstrated by an age- and sex-normalised mean change from baseline in BMI percentile, 4.3 over 1 year (average percentiles at baseline and
Skrbno kontroliranje telesne mase je pokazalo, da so imeli otroci in mladostniki, ki so v študiji jemali zdravilo Intuniv (zdravljenje 7 dni na teden eno leto), za starost in spol normalizirano povprečno spremembo percentila ITM od izhodišča 4,3 v enem letu (povprečna percentila v izhodišču in po
Careful haematological monitoring (including white blood cell and platelet count, and haemoglobin) should be performed during therapy with Myocet.
Med zdravljenjem z zdravilom Myocet je treba izvajati strog hematološki nadzor (vključno s štetjem belih krvnih celic in krvnih ploščic ter spremljanjem ravni hemoglobina).
Careful monitoring
Skrbno spremljanje.
Careful monitoring and dose adjustment of these drugs may be required.
Morda bosta potrebna skrbno spremljanje in prilagoditev odmerka teh zdravil.
Careful monitoring and evaluation for TFR is recommended.
Priporoča se skrbno spremljanje in ocenjevanje glede reakcije izbruha tumorja.
Careful monitoring of adverse reactions (e.g., respiratory depression, sedation) is recommended.
Priporoča se skrbno spremljanje neželenih učinkov (npr. respiratorna depresija, sedacija).
Careful monitoring of blood
Priporočljiv je natančen
Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g. uveitis) is recommended when rifabutin is coadministered with voriconazole.
Med sočasno uporabo rifabutina in vorikonazola je priporočljivo natančno nadziranje celotne krvne slike in neželenih učinkov rifabutina (npr. uveitisa).
Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is co-administered with voriconazole.
Med sočasno uporabo rifabutina in vorikonazola je priporočljivo natančno nadziranje celotne krvne slike in neželenih učinkov rifabutina (npr. uveitisa).
Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole.
Med sočasno uporabo rifabutina in vorikonazola je priporočljivo natančno nadziranje celotne krvne slike in neželenih učinkov rifabutina (npr. uveitisa).
Careful monitoring of phenytoin levels is recommended when phenytoin is co-administered with voriconazole.
Med sočasno uporabo fenitoina in vorikonazola je priporočljivo natančno nadziranje koncentracije fenitoina.
Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole.
Med sočasno uporabo fenitoina in vorikonazola je priporočljivo natančno nadziranje koncentracije fenitoina.
Careful monitoring of phenytoin plasma levels is recommended.
natančno nadziranje koncentracije fenitoina v plazmi.
Careful monitoring of the
Skrbno spremljanje prenašanja
Careful monitoring of the therapeutic effectiveness of P450 metabolised medicinal products is recommended when taken in combination with nevirapine.
Priporočeno je skrbno spremljanje terapevtskega učinka zdravil, ki se presnavljajo prek P450, kadar jih bolnik jemlje v kombinaciji z nevirapinom.
Careful monitoring of the tolerance to these anti-cancer agents is recommended.
Priporoča se skrbno spremljanje prenašanja teh zdravil proti raku.
Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with indinavir.
Kadar se deksometazon uporablja sočasno z indinavirjem, se priporoča skrbno spremljanje terapevtskih in neželenih učinkov.
Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with indinavir/ritonavir.
indinavirjem/ritonavirjem, se priporoča skrbno spremljanje terapevtskih in neželenih učinkov.
Careful monitoring of therapeutic and adverse effects is recommended when fexofenadine is concomitantly administered with indinavir/ritonavir.
Kadar se feksofenadin uporablja sočasno z indinavirjem/ritonavirjem, se priporoča skrbno spremljanje terapevtskih in neželenih učinkov.
Careful monitoring of therapeutic and adverse effects is recommended when morphine is concomitantly administered with indinavir/ritonavir.
Kadar se fentanil uporablja sočasno z indinavirjem/ritonavirjem, se priporoča skrbno spremljanje terapevtskih in neželenih učinkov.
Careful monitoring of therapeutic and adverse effects is recommended when tacrolimus is concomitantly administered with indinavir/ritonavir.
Kadar se takrolimus uporablja sočasno z indinavirjem/ritonavirjem, se priporoča skrbno spremljanje terapevtskih in neželenih učinkov.
Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir (see section 4.4).
Med sočasno uporabo teh zdravil in protiretrovirusnih odmerkov ritonavirja je priporočljivo natančno nadziranje terapevtskih in n eželenih učinkov (glejte poglavje 4.4).
Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses ofritonavir.
Med sočasno uporabo teh zdravil in protiretrovirusnih odmerkov ritonavirja je priporočljivo natančno nadziranje terapevtskih in neželenih učinkov .
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,
krbna izbira darovalcev krvi in plazme, da se zagotovi izključitev tveganj za prenos okužb,
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,
krbno izbiro darovalcev krvi in plazme za zagotavljanje, da bodo osebe, ki bi lahko prenašale okužbe, izključene,
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections.
krbna izbira darovalcev krvi in plazme, da se zagotovi izključitev tveganj za prenos okužb in testiranje prisotnosti virusov/okužb v vsaki darovani in zbrani plazmi.
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of viruses/infections.
krbna izbira darovalcev krvi in plazme, s čimer želimo zagotoviti, da so izključene osebe, ki bi lahko bile prenašalci okužb, preiskave vsake darovane enote in združene plazme na viruse in druge okužbe.
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded.
previdno izbiro darovalcev krvi in plazme za zagotovitev izključitve prenašalcev okužb,
Careful therapeutic drug monitoring
Zdravila po terapevtskih
Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.
Priporočljivi so skrbna oskrba ran in ukrepi za preprečevanje okužbe, še posebej če nekroza tkiva povzroči odprte rane.
Carefully attach the needle to the pre-filled syringe containing the colourless solution.
Iglo previdno pritrdite na napolnjeno injekcijsko brizgo, ki vsebuje brezbarvno raztopino.
Carefully consider benefits and risks before administering dabrafenib to patients with a prior or concurrent cancer associated with RAS mutations.
Pred uvedbo dabrafeniba bolnikom s predhodno ali trenutno prisotnim malignomom, ki je povezan z mutacijo RAS, je treba skrbno pretehtati koristi in tveganja takega zdravljenja.
Carefully draw exactly 6.0 ml sodium chloride 0.9%, solution for injection, into the 10 ml syringe.
Previdno izvlecite 6,0 ml 0,9 % raztopine natrijevega klorida za injiciranje v 10-ml brizgo.
Carefully expel the air from the syringe and adjust the dose to the 0.05 ml mark on the syringe.
Iz brizge previdno iztisnite zrak in odmerite vsebino do oznake 0,05 ml na brizgi.
Carefully follow all the other instructions given to you by your doctor, nurse or pharmacist.
Skrbno se ravnajte tudi po vseh drugih navodilih, ki jih dobite od svojega zdravnika, medicinske sestre ali farmacevta.
Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.
Natančno upoštevajte tudi vsa druga navodila, ki jih dobite od svojega zdravnika, farmacevta ali medicinske sestre.
Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.
Skrbno se ravnajte tudi po vseh drugih navodilih, ki jih dobite od svojega zdravnika, farmacevta ali medicinske sestre.
Carefully insert a pressure-venting device equipped with a hydrophobic filter.
Previdno vstavite napravo za sproščanje tlaka, opremljeno s hidrofobnim filtrom.
Carefully inspect the solution before injecting it and use only if clear and colourless.
Pred injiciranjem skrbno preglejte raztopino in jo uporabite le, če je bistra in brezbarvna.
carefully monitored and the
natančno nadzirati in njegov
carefully monitored and the dose
natančno nadzirati in njegov
carefully monitored.
ciklosporina skrbno nadzirati.
Carefully peel off the backing
Previdno odstranite zgornjo papirnato plast
Carefully place the open ampoule upright on the work- surface.
Odprto ampulo previdno položite v pokončnem položaju na delovno površino.
CAREFULLY press the plunger until it cannot go further and hold the plunger down
PREVIDNO potisnite bat do konca in ga držite v tem položaju.
Carefully pull back the plunger to correct level on syringe (e.g.
Previdno povlecite bat nazaj na pravilno raven na injekcijski brizgi (npr.
Carefully pull the cap away from the body of the capsule (illustration c).
Previdno povlecite pokrovček s telesa kapsule (slika c).
Carefully pull the grey needle cap straight out and away from your body.
Previdno potegnite sivi pokrovček igle naravnost z brizge in proč od telesa.
Carefully pull the grey needle cap straight out and away from your body.
Skrbno potegnite sivi pokrovček igle naravnost z nje in proč od vašega telesa.
Carefully pull the needle cover straight off.
Z ravnim potegom previdno odstranite pokrovček igle.
Carefully push the plunger upwards until a tiny droplet appears at the tip of the needle.
Previdno potisnite bat navzgor, da se bo na vrhu igle pojavila majhna kapljica.
Carefully put the outer needle cap onto the needle.
Previdno namestite zunanji pokrovček igle na injekcijsko iglo.
Carefully put the outer needle shield back over the needle.
Previdno namestite zunanjo zaščito igle nazaj na iglo.
Carefully read all the information about hypersensitivity reactions in Section 4.
Natančno preberite vse informacije o preobčutljivostnih reakcijah v poglavju 4. če imate hude težave z ledvicami .
Carefully read all the information about hypersensitivity reactions in Section 4. if you are taking a medicine called dofetilide (to treat heart conditions).
Natančno preberite vse informacije o preobčutljivostnih reakcijah v poglavju 4. če jemljete zdravilo, ki vsebuje dofetilid (za zdravljenje bolezni srca).
Carefully read the Manufacturer’s Instructions for Use, provided with your Zirela Nebuliser Handset.
Natančno preberite proizvajalčeva navodila za uporabo, priložena nebulatorju Zirela.
Carefully read the package leaflet of all other HIV medicinal products you are taking in combination with Viramune.
Natančno preberite navodila za uporabo vseh drugih zdravil, ki jih boste jemali zaradi okužbe s HIV v kombinaciji z zdravilom Viramune.
Carefully read the package leaflet of all other HIV medicines you are taking in combination with Viramune.
Natančno preberite navodila za uporabo vseh drugih zdravil, ki jih boste jemali zaradi okužbe s HIV v kombinaciji z zdravilom Viramune.
Carefully read the ‘Instructions on how to use’ on the other side of this leaflet and use the pen as described.
Natančno preberite “Navodila za uporabo” na drugi strani tega navodila in injekcijski peresnik uporabljajte v skladu s temi navodili.
Carefully remove and discard the green inner shield.
Previdno odstranite in zavrzite notranji zeleni ščitnik.
Carefully remove any existing patch before putting on a new one.
Preden namestite nov obliž, previdno odstranite prešnjega.
Carefully remove the blister package from the Mix2Vial set by holding at the rim, and pulling vertically upwards.
Gangið úr skugga um að eingöngu þynnupakkningin sé fjarlægð en ekki Mix2Vial settið.
Carefully remove the blister package from the Mix2Vial set by holding at the rim, and pulling vertically upwards.
Previdno odstranite pretisni omot s kompleta Mix2Vial, tako da ga primete za obod in potegnete navpično navzgor.
Carefully remove the cap from the injection needle without disconnecting the injection needle from the syringe.
Pozor: Pri odstranjevanju pokrovčka držite injekcijsko iglo za rumeni obod.
Carefully remove the cap from the injection needle without disconnecting the injection needle from the syringe.
Previdno snemite pokrovček z injekcijske igle, ne da bi pri tem iglo sneli z brizge.
Carefully remove the oral syringe from the patient’s mouth.
Previdno potegnite brizgo iz bolnikovih ust.
Carefully remove the outer needle cap, then the inner needle cap.
Previdno odstranite najprej zunanji pokrovček in nato še notranji pokrovček igle.
Carefully remove the rubber stopper.
Previdno odstranite gumijasti zamašek.
Carefully replace the outer injection needle cap (see Diagram Q).
Previdno postavite zunanji pokrovček injekcijske igle nazaj na iglo (glejte sliko Q).
Carefully replace the outer needle shield.
Previdno znova namestite zaščito zunanje igle.
Carefully turn the vial upside down.
Previdno zasukajte vialo na glavo.
Carefully wipe off the extra ointment.
Preveliko količino mazila previdno obrišite.
carefully wipe off the ointment contact your doctor or pharmacist immediately.
nemudoma se posvetujte s svojim zdravnikom ali farmacevtom.
Carefully withdraw the required volume depending on the dose to be administered (0.2 ml to 1.0 ml) and subcutaneously inject using a 27 G x 0.5 inch (13 mm) needle.
Previdno izvlecite toliko raztopine, kolikor je potrebno za injiciranje predpisanega odmerka (od 0,2 ml do 1,0 ml), in subkutano injicirajte raztopino z uporabo igle 27 G x 0,5 palca (13 mm).
Carefully withdraw the required volume depending on the dose to be administered (0.2 ml to 1.0 ml) and subcutaneously inject using the safety needle provided in the kit.
Previdno izvlecite toliko raztopine, kolikor je potrebno za injiciranje predpisanega odmerka (od 0,2 ml do 1,0 ml), in subkutano injicirajte raztopino z uporabo varnostne igle, ki je priložena v kompletu.
Caregivers administering Valtropin to their children should consider that ‘you’ refers to the child.
Skrbniki, ki dajejo zdravilo Valtropin otrokom, morajo vedeti, da "vi" pomeni otroka.
Caregivers must be very careful when handling used needles – to prevent needle injury and cross-infection. especially children.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da se ne bi zbodle in okužile. drugim lahko škodilo.
Caregivers must be very careful when handling used needles – to prevent needle injury and cross­infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da preprečijo poškodbe z iglami in navzkrižno okužbo.
Caregivers must be very careful when handling used needles – to reduce the risk of needle injury and cross-infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da se ne bi zbodle in okužile.
Caregivers must be very careful when handling used needles – to reduce the risk of needle sticks and cross-infection
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami nadvse pazljive, da zmanjšajo tveganje za vbode z iglami in prenos okužb.
Caregivers must be very careful when handling used needles – to reduce the risk of needle sticks and cross-infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami nadvse pazljive, da zmanjšajo tveganje za vbode z iglami in prenos okužb.
Caregivers must be very careful when handling used needles –to reduce the risk of needle injury and cross- infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da se ne bi zbodle in okužile.
Caregivers must be very careful when handling used needles –to reduce the risk of needle sticks and cross-infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami nadvse pazljive, da zmanjšajo tveganje za vbode z iglami in prenos okužb.
Caregivers should be most careful when handling used needles to avoid needle sticks.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami nadvse pazljive, da se z njimi ne zbodejo.
Caregivers should be most careful when handling used needles to avoid needle sticks.
Osebe, ki skrbijo za bolnika, morajo z uporabljenimi iglami ravnati nadvse pazljivo, da se z njimi ne zbodejo.
Caregivers should not open capsules to avoid exposure to the contents of the capsule.
Skrbniki bolnikov naj ne odpirajo kapsul, da ne bodo prišli v stik z vsebino kapsule.
Caregivers should not open the capsules to avoid exposure to the contents of the capsule.
Skrbniki bolnikov naj ne odpirajo kapsul, da ne bodo prišli v stik z vsebino kapsule.
Caregivers should provide assistance to children starting TOBI Podhaler treatment, particularly those aged 10 years or younger, and should continue to supervise them until they are able to use the Podhaler device properly without help.
Otrokom, ki začenjajo zdravljenje z zdravilom TOBI Podhaler, zlasti tistim, ki so stari 10 let ali manj, naj pri uporabi zdravila pomagajo negovalci in z nadzorovanjem nadaljujejo tako dolgo, da se otroci naučijo ustrezno uporabljati inhalator Podhaler povsem samostojno.
Caregivers should wear disposable gloves when handling the tablets.
Skrbniki naj pri rokovanju z zdravilom nosijo rokavice za enkratno uporabo.
Carers should only administer a single dose of midazolam.
Negovalec naj da en odmerek midazolama.
Carglumic acid is more resistant than N-acetylglutamate to hydrolysis by aminoacylase present in the cytosol.
Kargluminska kislina je v primerjavi z N-acetilglutamatom bolj odporna na hidrolizo z aminoacilazo v citosolu.
Carglumic acid responsiveness test
Test odgovora na kargluminsko kislino
Caring for your pen
Vzdrževanje
Caring for your pen
Vzdrževanje injekcijskega peresnika
Carisoprodol
karisoprodol Posamezen
Carmellose calcium Hydroxypropyl cellulose Lactose monohydrate Magnesium stearate
kalcijev karmelozat hidroksipropilceluloza laktoza monohidrat magnezijev stearat
Carmellose calcium Hydroxypropylcellulose Lactose monohydrate Magnesium stearate
kalcijev karmelozat hidroksipropilceluloza laktoza monohidrat magnezijev stearat
Carmellose calcium HydroxypropylcelluloseLactose monohydrate Magnesium stearate
kalcijev karmelozat hidroksipropilceluloza laktoza monohidrat magnezijev stearat
Carmellose powder for implantation suspension for Opgenra Intraosseous use
Karmeloza, prašek za suspenzijo za implantacijo za zdravilo Opgenra. intraosalna uporaba
carmellose sodium (E466) sodium chloride
natrijev karmelozat (E466) natrijev klorid
Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide
Natrijev karmelozat, manitol, natrijev dihidrogenfosfat monohidrat, natrijev hidroksid
CARMELLOSE VIAL
VIALA S KARMELOZO
Carnauba wax
Glazura karnauba vosek.
Carotene decreased International normalised ratio abnormal
znižana raven kalija v krvi, znižana raven karotena, nenormalno mednarodno umerjeno razmerje,
Carpal Tunnel
indrom karpalnega kanala
Carpal Tunnel Syndrome
indrom karpalnega kanala
carrier
ampula
Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Humira, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV.
Carriers of HBV who require treatment with Simponi should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Prenašalce virusa HBV, ki potrebujejo zdravljenje z zdravilom Simponi, natančno spremljajte, da boste pri njih ugotovili morebitne znake in simptome aktivne okužbe s HBV skozi ves čas zdravljenja in še nekaj mesecev po prenehanju zdravljenja.
Carriers of HBV who require treatment with Trudexa should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Nosilce HBV, ki potrebujejo zdravljenje s Trudexo, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV.
Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with Bortezomib Hospira.
Prenašalce virusa hepatitisa B in bolnike, ki so že bili okuženi z virusom hepatitisa B, je treba med zdravljenjem in v nadaljevanju zdravljenja z rituksimabom v kombinaciji z zdravilom Bortezomib Hospira skrbno spremljati glede kliničnih in laboratorijskih znakov aktivne okužbe s HBV.
Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with bortezomib.
Prenašalce virusa hepatitisa B in bolnike, ki so že bili okuženi z virusom hepatitisa B, je treba med zdravljenjem in v nadaljevanju zdravljenja z rituksimabom v kombinaciji z bortezomibom skrbno spremljati glede kliničnih in laboratorijskih znakov aktivne okužbe s HBV.
Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with VELCADE.
Prenašalce virusa hepatitisa B in bolnike, ki so že bili okuženi z virusom hepatitisa B, je treba med zdravljenjem in v nadaljevanju zdravljenja z rituksimabom v kombinaciji z zdravilom VELCADE skrbno spremljati glede kliničnih in laboratorijskih znakov aktivne okužbe s HBV.
Carriers of the virus are likely to get serious liver problems, such as “cirrhosis” or liver cancer.
Pri nosilcih virusa obstaja verjetnost resnih težav z jetri, npr. ciroze ali raka jeter.
Carrigaline County Cork Ireland
Carrigaline, County Cork, Irska
Carrigaline, County Cork, Ireland
Currabinny, Carrigaline, County Cork, Irska
CARRY CASE (SHUTTLE)
ŠKATLICA ZA PRENOS (SHUTTLE)
Carry on taking your current asthma medicine during Xolair treatment.
Med zdravljenjem z zdravilom Xolair nadaljujte z jemanjem svojega dosedanjega zdravila proti astmi.
CART has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
Kombinirano protiretrovirusno zdravljenje je bilo povezano s presnovnimi nepravilnostmi, kot so hipertrigliceridemija, hiperholesterolemija, odpornost na insulin, hiperglikemija in hiperlaktatemija (glejte poglavje 4.4).
Cartilage is a tissue that is present in every joint in the body; it protects the ends of bones and allows joints to function smoothly.
Hrustanec je tkivo, ki ga najdemo v vsakem sklepu v telesu; ščiti skrajne dele kosti in omogoča gladko gibanje sklepov.
Cartilage is a tissue that is present in every joint.
Hrustanec je tkivo, prisotno v vsakem sklepu.
CARTON
KARTONSKA ŠKATLA
CARTON
PRETISNI OMOT
CARTON
ZUNANJA ŠKATLA
Carton
{Škatla}
CARTON
ŠK ATLA
Carton
Škatla
CARTON
ŠKATLA/
CARTON
ŠKATLICA
CARTON
škatla
CARTON ( Containing 30 sachets)
ŠKATLA (s 30 vrečicami)
Carton (1 pre-filled syringe)
Kartonska škatla (1 napolnjena brizga)
Carton (10 mg/2 ml)
Škatla (10 mg/2 ml)